about
Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerMicroenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticityContext matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trialsBenefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept studyAnalytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular SubtypesCorrection: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
P50
Q38956018-32D3FD5A-5A44-4A86-8C85-097E98299CABQ53707065-E0797F88-2D55-455F-A201-DA043FAB005DQ57799070-EB4F8A7C-BC0F-456A-AAA9-8EF5CCF6A035Q58698836-FF2CF868-45C9-4C92-8262-1B001765E1DBQ64107999-CEAB049A-66F5-406C-9462-8E9EB83A4D38Q64114213-1E1419A5-BDBD-4A9F-BC91-A4A45027DABFQ64273639-EECFC717-4875-404B-90CE-0DE5750DF4FFQ92419520-05B6638A-AD45-4961-B8B5-3884CA657FEC
P50
description
researcher ORCID ID = 0000-0001-6903-9067
@en
wetenschapper
@nl
name
Katherine Eason
@ast
Katherine Eason
@en
Katherine Eason
@es
Katherine Eason
@nl
type
label
Katherine Eason
@ast
Katherine Eason
@en
Katherine Eason
@es
Katherine Eason
@nl
prefLabel
Katherine Eason
@ast
Katherine Eason
@en
Katherine Eason
@es
Katherine Eason
@nl
P106
P21
P31
P496
0000-0001-6903-9067